PANLAR consensus statement on biosimilars.
Sergio KowalskiJ A BenavidesP A B RoaC Galarza-MaldonadoC V Caballero-UribeE R SorianoC PinedaV F AzevedoG Avila-PedrettiA M BabiniA Cachafeiro-VilarM Cifuentes-AlvaradoS B CohenP E DíazL Diaz SotoC EncaladaB GarroI A G SariegoM Guibert-ToledanoV J K RodriguezM E L LopezA P OrtegaA S RussellP Santos-MorenoI S TeránA VargasG VásquezR M XavierD X Xibillé FiredmanE MyslerJ KayPublished in: Clinical rheumatology (2019)
• Biologics have improved the treatment of rheumatic diseases. • Their high cost limits access for many patients in both North America and Latin America. • Biosimilars typically are less expensive, providing additional treatment options for patients with rheumatic diseases. • PANLAR presents its consensus on biosimilars in rheumatology.